Literature DB >> 7915496

Molecular basis for somatostatin action: inhibition of c-fos expression and AP-1 binding.

A Todisco1, V Campbell, C J Dickinson, J DelValle, T Yamada.   

Abstract

The mechanisms by which somatostatin exerts its widespread inhibitory actions have been investigated extensively but understood only partially. Recent studies have shown that somatostatin can inhibit gene transcription directly. In view of the critical importance of early response genes in induction of gene expression, we examined whether the action of somatostatin might be mediated by inhibition of early response genes. The products of some of these genes, such as c-fos and c-jun, are known to form a heterodimeric transcription factor complex (AP-1) that binds specifically to the consensus sequence TGAC(G)TCA. Accordingly, we examined the effects of somatostatin on c-fos gene expression and on the binding of the AP-1 complex to its specific DNA element using isolated gastric parietal cells and the GH3 pituitary cell line. In both parietal and GH3 cells, c-fos-specific mRNA was increased by agents known to act via both adenosine-3',5'-cyclic monophosphate and Ca(2+)-dependent signaling mechanisms, and octreotide significantly inhibited this response. Pertussis toxin pretreatment (200 ng/ml) reversed the inhibitory effect of octreotide. AP-1 binding activity, assessed by gel shift assays using a 32P-labeled AP-1 oligonucleotide probe, was stimulated by dibutyryl adenosine 3',5'-cyclic monophosphate and serum and inhibited by octreotide treatment. Our observations support the notion that the universal inhibitory action of somatostatin may be mediated by inhibition of expression of early response genes via a pertussis toxin-sensitive inhibitory pathway. This effect appears to lead to decreased binding of regulatory nuclear proteins to their specific DNA elements resulting, presumably, in diminished gene expression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7915496     DOI: 10.1152/ajpgi.1994.267.2.G245

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  6 in total

1.  Negative regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5.

Authors:  Guisheng Zhou; Shi-He Liu; Kelly M Shahi; Hua Wang; Xueyan Duan; Xia Lin; Xin-Hua Feng; Min Li; William E Fisher; Francesco J Demayo; David Dawson; F Charles Brunicardi
Journal:  Mol Endocrinol       Date:  2012-06-05

2.  Native somatostatin sst2 and sst5 receptors functionally coupled to Gi/o-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs.

Authors:  Davide Cervia; Dominique Fehlmann; Daniel Hoyer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-05-15       Impact factor: 3.000

Review 3.  Neuroendocrine neoplasia of the gastrointestinal tract revisited: towards precision medicine.

Authors:  Guido Rindi; Bertram Wiedenmann
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

4.  Octreotide Effect on Growth Hormone and Somatostatin Subtype 2 Receptor mRNAs of the Human Pituitary Somatotroph Adenomas.

Authors:  Lucia Stefaneanu; Kalman Kovacs; Kamal Thapar; Eva Horvath; Shlomo Melmed; Yona Greenman
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

Review 5.  Down-regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5: a novel mechanism for inhibition of cellular proliferation and insulin secretion by somatostatin.

Authors:  Guisheng Zhou; Jim Sinnett-Smith; Shi-He Liu; Juehua Yu; James Wu; Robbi Sanchez; Stephen J Pandol; Ravinder Abrol; John Nemunaitis; Enrique Rozengurt; F Charles Brunicardi
Journal:  Front Physiol       Date:  2014-06-25       Impact factor: 4.566

6.  Long-term effects of somatostatin analogues in rat GH-secreting pituitary tumor cell lines.

Authors:  A Dicitore; D Saronni; G Gaudenzi; S Carra; M C Cantone; M O Borghi; L Persani; G Vitale
Journal:  J Endocrinol Invest       Date:  2021-06-14       Impact factor: 4.256

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.